SynthesisSpine2016
Safety and Local Control of Radiation Therapy for Chordoma of the Spine and Sacrum: A Systematic Review.
Synthesis in Spine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
44 citing papers in PubMed, 6 syntheses or guidelines pooled it, 117 citations in OpenAlex.
- Stereotactic radiosurgery (SRS) for primary spinal bone tumors: a systematic review and meta-analysis.Neurosurgical review · 2025Pooled it
- Efficacy and safety of proton radiotherapy in treating choroidal melanoma: a systematic review and meta-analysis.Radiation oncology (London, England) · 2025Pooled it
- Efficacy and safety of carbon ion radiotherapy for bone sarcomas: a systematic review and meta-analysis.Radiation oncology (London, England) · 2022Pooled it
- Pure proton therapy for skull base chordomas and chondrosarcomas: A systematic review of clinical experience.Frontiers in oncology · 2022Pooled it
- Cervical chordomas: multicenter case series and meta-analysis.Journal of neuro-oncology · 2021Pooled it
- Targeted Therapy for Chordoma: Key Molecular Signaling Pathways and the Role of Multimodal Therapy.Targeted oncology · 2021Pooled it
- Case Report: Anlotinib for advanced chordoma.Frontiers in oncology · 2026Article
- Evaluation of crizotinib as radiosensitizer in sacral chordoma cells: effects of combined carbon ion particle therapy.Medical oncology (Northwood, London, England) · 2025Article
- Review
- Recurrence Patterns After Resection of Sacral Chordoma: Toward an Optimized Postoperative Target Volume Definition.Cancers · 2025Article
- Carbon-ion radiotherapy induces ferroptosis and M1 macrophage polarization to inhibit the development of gastric cancer by downregulating DHODH.Frontiers in medicine · 2025Article
- Therapeutic strategies for mobile spine chordoma: en bloc Versus intralesional surgery with adjuvant charged-particle therapy.Journal of neuro-oncology · 2025Article
- Insufficiency fractures in patients with sacral chordoma treated with high-dose radiation therapy with and without resection.BJR open · 2025Article
- Tailored surgical approaches for spinal chordomas: A multidisciplinary perspective.Acta neurochirurgica · 2024Article
- Chordoma: Genetics and Contemporary Management.International journal of molecular sciences · 2024Review
- A Prospective Phase I/II Clinical Trial of High-Dose Proton Therapy for Chordomas and Chondrosarcomas.Advances in radiation oncology · 2024Article
- Sacral-Nerve-Sparing Planning Strategy in Pelvic Sarcomas/Chordomas Treated with Carbon-Ion Radiotherapy.Cancers · 2024Article
- Chordoma: demographics and survival analysis with a focus on racial disparities and the role of surgery, a U.S. population-based study.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2024Article
- Exceptionally giant neglected sacral chordoma in a post-poliotic residual paralysis patient - a rare case scenario.American journal of neurodegenerative disease · 2024Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 3 countries.
Funding
Abstract
STUDY
designSystematic literature review.
objectiveTo assess the toxicity, common radiation doses, and local control (LC) rates of radiation therapy for chordoma of the spine and sacrum and identify the difference in LC and toxicity between adjuvant, salvage, and primary therapy using radiation. SUMMARY OF BACKGROUND DATA: Chordoma of the spine is typically a low-grade malignant tumor thought to be relatively radioresistant with a high rate of local recurrence and the potential for metastases. Improved results of modern radiation therapy in the treatment of chordoma support exploration of its role in the management of primary/de novo chordoma or recurrent chordoma.
methodsWe conducted a systematic literature review using PubMed and Embase databases to assess information available regarding the toxicity, LC rates, and overall survival (OS) rates for adjuvant, salvage, and primary radiation therapy for spinal and sacral chordoma.
resultsA total of 40 articles were reviewed. Evidence quality was low or very low. The highest rates of LC and OS were with early adjuvant RT for primary/de novo disease. Salvage RT for recurrent disease has very small cohorts and thus strong conclusions were not able be made.
conclusionThe use of pre- and/or post-operative photon image-guided radiotherapy (IGRT), proton or carbon ion therapy should be considered for patients undergoing surgery for the treatment of primary and recurrent chordomas in the mobile spine and sacrum, since these RT modalities may improve local control. Preoperative evaluation by the surgeon and radiation oncologist should be used to formulate a cohesive treatment plan.The use of photon IGRT or carbon ion therapy as the primary treatment of chordoma, when currently in its developmental stage, shows promise and requires clear delineation of toxicity profile and long-term local control. LEVEL OF EVIDENCE: 2.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.